相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tumor-Associated Macrophages in Hepatocellular Carcinoma: Friend or Foe?
Dexi Zhou et al.
GUT AND LIVER (2021)
Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma
Kohei Shigeta et al.
HEPATOLOGY (2020)
Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Interim analysis of the prospective, observational REFINE trial.
Ho Yeong Lim et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Epidemiology and surveillance for hepatocellular carcinoma: New trends
Amit G. Singal et al.
JOURNAL OF HEPATOLOGY (2020)
Molecular therapies for HCC: Looking outside the box
Sandrine Faivre et al.
JOURNAL OF HEPATOLOGY (2020)
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
Ann-Lii Cheng et al.
JOURNAL OF HEPATOLOGY (2020)
Efficacy of Regorafenib in Hepatocellular Carcinoma Patients: A Systematic Review and Meta-Analysis
Antonio Facciorusso et al.
CANCERS (2020)
Regorafenib-loaded poly (lactide-co-glycolide) microspheres designed to improve transarterial chemoembolization therapy for hepatocellular carcinoma
Xiang Li et al.
ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES (2020)
Optimized management of nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma (RCC): A response-based phase II study (OMNIVORE).
Rana R. McKay et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
FRACTION-RCC: Innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell carcinoma (aRCC).
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Sequential treatment with sorafenib (SOR) followed by regorafenib (REG) in patients (pts) with unresectable hepatocellular carcinoma (HCC): Interim analysis of the observational REFINE study.
Philippe Merle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260).
Michael B. Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events
Changhoon Yoo et al.
LIVER INTERNATIONAL (2020)
Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab
Andrea S. Fung et al.
CANCER MEDICINE (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Intrahepatic Tumor Burden as a Novel Factor Influencing the Introduction of Second-line Chemotherapy for Hepatocellular Carcinoma
Michihisa Moriguchi et al.
ANTICANCER RESEARCH (2020)
Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: A multicentre retrospective study
Hyung-Don Kim et al.
LIVER INTERNATIONAL (2020)
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial
Thomas Yau et al.
JAMA ONCOLOGY (2020)
Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date
Alison L. Raybould et al.
JOURNAL OF HEPATOCELLULAR CARCINOMA (2020)
A PHASE 3 STUDY (COSMIC-313) OF CABOZANTINIB IN COMBINATION WITH NIVOLUMAB AND IPILIMUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA OF INTERMEDIATE OR POOR RISK
Toni Choueiri et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma
Leonardo G. da Fonseca et al.
CLINICS IN LIVER DISEASE (2020)
Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma
Kohei Shigeta et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma
Michael Teufel et al.
GASTROENTEROLOGY (2019)
Natural killer group 2D receptor and its ligands in cancer immune escape
Shixin Duan et al.
MOLECULAR CANCER (2019)
Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond
Masatoshi Kudo
WORLD JOURNAL OF GASTROENTEROLOGY (2019)
Regorafenib may enhance efficacy of anti-program cell death-1 therapy in hepatocellular carcinoma through modulation of macrophage polarization
Chia-Wei Chen et al.
JOURNAL OF HEPATOLOGY (2019)
Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation
Massimo Iavarone et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2019)
Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers
Flavia Fondevila et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2019)
Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study
Tanios S. Bekaii-Saab et al.
LANCET ONCOLOGY (2019)
Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma
Hitomi Takada et al.
CANCERS (2019)
Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma-Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
Wan Wang et al.
CANCERS (2019)
Systemic Therapy for Advanced Hepatocellular Carcinoma in an Evolving Landscape
Kabir Mody et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2019)
Molecular insight of regorafenib treatment for colorectal cancer
Hiroyuki Arai et al.
CANCER TREATMENT REVIEWS (2019)
Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma
Changhoon Yoo et al.
INVESTIGATIONAL NEW DRUGS (2019)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2019)
Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinoma
Atsushi Yukimoto et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2019)
Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment
Sadahisa Ogasawara et al.
INVESTIGATIONAL NEW DRUGS (2018)
Analysis of the liver functional reserve of patients with advanced hepatocellular carcinoma undergoing sorafenib treatment: Prospects for regorafenib therapy
Takeshi Terashima et al.
HEPATOLOGY RESEARCH (2018)
Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice
Shinsuke Uchikawa et al.
HEPATOLOGY RESEARCH (2018)
Novel approaches for molecular targeted therapy against hepatocellular carcinoma
Yuji Eso et al.
HEPATOLOGY RESEARCH (2018)
Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib
Man Tong et al.
JOURNAL OF HEPATOLOGY (2018)
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial
Richard S. Finn et al.
JOURNAL OF HEPATOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Dal Fukurnura et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma
Anna Tutusaus et al.
Oncotarget (2018)
Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer
Gordon C. Jayson et al.
NATURE COMMUNICATIONS (2018)
The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension
Frank Erhard Uschner et al.
Oncotarget (2018)
Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib.
Jordi Bruix et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Immunotherapy for hepatocellular carcinoma: current status and future perspectives
Takuji Okusaka et al.
ESMO OPEN (2018)
Circulating angiogenesis-related markers as predictors of benefit from regorafenib in metastatic colorectal cancer (mCRC) patients (pts).
Carlotta Antoniotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012
Donna L. White et al.
GASTROENTEROLOGY (2017)
Survival by pattern of tumor progression during prior sorafenib (SOR) treatment in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial comparing second-line treatment with regorafenib (REG) or placebo.
Jordi Bruix et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study
Kim A. Reiss et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Comparison of modified (m)RECIST and RECIST 1.1 assessments in the phase 3 RESORCE trial comparing regorafenib and placebo in patients with hepatocellular carcinoma who progressed during sorafenib treatment
J. Bruix et al.
JOURNAL OF HEPATOLOGY (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis
Alessandro Granito et al.
LANCET ONCOLOGY (2017)
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
Lin Tian et al.
NATURE (2017)
A Multikinase and DNA-PK Inhibitor Combination Immunomodulates Melanomas, Suppresses Tumor Progression, and Enhances Immunotherapies
Alexander K. Tsai et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
Michael A. Cannarile et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Radiologic criteria of response to systemic treatments for hepatocellular carcinoma
Francesco Tovoli et al.
HEPATIC ONCOLOGY (2017)
Tumor-associated macrophages in cancers
W. Hu et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2016)
Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib
Alessandro Granito et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2016)
Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models
Dieter Zopf et al.
CANCER MEDICINE (2016)
Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response
Bryony Simmons et al.
CLINICAL INFECTIOUS DISEASES (2015)
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach-The ALBI Grade
Philip J. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer
Jia-Yu Liu et al.
MOLECULAR THERAPY (2015)
Hepatocellular carcinomas promote tumor-associated macrophage M2-polarization via increased B7-H3 expression
Fu-Biao Kang et al.
ONCOLOGY REPORTS (2015)
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Rakesh K. Jain
CANCER CELL (2014)
STAT3 Mediates Regorafenib-Induced Apoptosis in Hepatocellular Carcinoma
Wei-Tien Tai et al.
CLINICAL CANCER RESEARCH (2014)
Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer
Roberta Schmieder et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team
Jessica Dyson et al.
JOURNAL OF HEPATOLOGY (2014)
Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective
Roelof W. F. van Leeuwen et al.
LANCET ONCOLOGY (2014)
Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study
Jordi Bruix et al.
EUROPEAN JOURNAL OF CANCER (2013)
Regorafenib Inhibits Growth, Angiogenesis, and Metastasis in a Highly Aggressive, Orthotopic Colon Cancer Model
Lotfi Abou-Elkacem et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study
D. Strumberg et al.
BRITISH JOURNAL OF CANCER (2012)
Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
Hashem B. El-Serag
GASTROENTEROLOGY (2012)
The changing scenario of hepatocellular carcinoma over the last two decades in Italy
Valentina Santi et al.
JOURNAL OF HEPATOLOGY (2012)
Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace
Gyoergy Baffy et al.
JOURNAL OF HEPATOLOGY (2012)
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
Yuhui Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Field-Practice Study of Sorafenib Therapy for Hepatocellular Carcinoma: A Prospective Multicenter Study in Italy
Massimo Iavarone et al.
HEPATOLOGY (2011)
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
Scott M. Wilhelm et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in Patients With Hepatitis C Virus-Related Cirrhosis
Ashwani K. Singal et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2010)
Outcome of Sustained Virological Responders With Histologically Advanced Chronic Hepatitis C
Timothy R. Morgan et al.
HEPATOLOGY (2010)
Metabolic Syndrome and Hepatocellular Carcinoma Two Growing Epidemics With a Potential Link
Abby B. Siegel et al.
CANCER (2009)
Vascular normalization in Rgs5-deficient tumours promotes immune destruction
Juliana Hamzah et al.
NATURE (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
分享论文
